CAS: 1998725-11-3

JHU-083 is an investigational therapeutic agent, which is a potent small molecule inhibitor of glutamine metabolism. It originates from academic institutions focused on advancing biomedical research. The mode of action of JHU-083 involves the inhibition of glutaminase, an enzyme critical for converting glutamine to glutamate, a key energy source for proliferating cells. By impeding this metabolic pathway, JHU-083 effectively starves cancer cells of the necessary components for growth and survival. In scientific research, JHU-083 is utilized primarily to study the modulation of tumor immune microenvironments and the reprogramming of immune cell metabolism. Its applications extend into cancer immunotherapy, where it facilitates the investigation of new therapeutic approaches combining metabolic inhibition with immune modulation strategies. Additionally, JHU-083 serves as a promising tool for exploring the metabolic dependencies of various malignancies, contributing to the broader understanding of tumor biology and paving the way for novel interventions.

JHU-083 is a glutaminase antagonist that improves cognition and normalizes aberrant hippocampal glutaminase activity in APOE4 mice.